August 9, 2005 Biotech snapped its three-day losing streak, with the Centient Biotech 200 climbing more than 22 points to 3702.69, a rise of .61%. Biogen Idec and Elan led the charge upward after raising hopes that Tysabri can be marketed safely, New River announced new priorities for its drug candidates, Boston Scientific loaned Celsion $15 million to continue work on its heat-related cancer therapies, Memory took a hit after releasing its Q2 financials, and Lipid may put itself up for sale. More details...
